You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
GenomeWeb asked a number of prominent researchers in the field via email about their top picks for notable developments or achievements in genomics during the 2010s.
Investigators worldwide are sharing data to search for features in the human genome that might contribute to COVID-19 susceptibility or progression.
An integrated analysis involving prostate cancer patients from China highlighted frequent FOXA1 mutations and deletions in two other genes.
A nationwide, multi-agency effort to sequence the virus causing COVID-19 is a logistical nightmare, but experts say the UK is well situated to succeed.
Though it is unclear whether the virus became pathogenic before or after the jump from animals to humans, genomic features point to a natural source for the COVID-19 coronavirus.
The clinics see patients whose overall health may benefit from learning about their genetic predisposition for certain medical conditions.
Researchers re-examined whole-genome and whole-transcriptome sequencing TCGA studies from 33 cancer types and found unique microbial signatures.
Invitae said YouScript and Genelex will enable it to provide pharmacogenomic testing, while Diploid will help interpret WGS results.
The insurer will cover testing at the Rady Children's Institute for Genomic Medicine for children in intensive care with unexplained medical conditions.
Bioinformatics firm Next Gen Diagnostics will integrate Fluidigm's Juno microfluidic sample prep system into its workflow for pathogen whole-genome sequencing.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.